 |
71 Diseases |  |
99 Trials |
|
99 Trials |  |
2781 News |  |
| 12345678910111213...3738» |
- || Halaven (eribulin mesylate) / Eisai
Review, Journal: Eribulin in breast cancer: Current insights and therapeutic perspectives. (Pubmed Central) - Jul 1, 2024
Since approval, there has been a surge in studies investigating the application of eribulin as an earlier-line treatment and also in combination with other agents such as immunotherapy and targeted therapy across all breast cancer sub-types, including hormone receptor positive, HER2 positive and triple negative breast cancer, many demonstrating promising activity. This review will focus on the application of eribulin in the treatment of metastatic breast cancer across all subtypes including its role as an earlier-line agent, its toxicity profile, and potential future directions.
- | Halaven (eribulin mesylate) / Eisai
Preclinical, Journal: The effects of the combination of temozolomide and Eribulin on T98G human glioblastoma cell line: an ultrastructural study. (Pubmed Central) - Jun 25, 2024
In conclusion, the similarity in the mechanism of action between ERB and TMZ suggests the potential for synergistic effects when combined. Our results highlight that this combination induced severe damage and autophagy in glioma spheroids after 48?hours.
- | Halaven (eribulin mesylate) / Eisai
Journal, Circulating tumor DNA, Metastases: Circulating tumour DNA dynamics during alternating chemotherapy and hormonal therapy in metastatic breast cancer: the ALERT study. (Pubmed Central) - Jun 17, 2024
P2
Our results highlight that this combination induced severe damage and autophagy in glioma spheroids after 48?hours. Changes in ctDNA can occur rapidly and reflect changes in patients' clinical tumour responses (NCT02681523).
- ||||| Herceptin (trastuzumab) / Roche, Kisqali (ribociclib) / Novartis, Perjeta (pertuzumab) / Roche
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases: Detect V / CHEVENDO (Chemo vs. Endo) (clinicaltrials.gov) - Jun 3, 2024
P3, N=271, Active, not recruiting, Sponsor: Prof. Wolfgang Janni
Changes in ctDNA can occur rapidly and reflect changes in patients' clinical tumour responses (NCT02681523). Recruiting --> Active, not recruiting | Trial completion date: Nov 2024 --> Jan 2025 | Trial primary completion date: Sep 2024 --> Jan 2025
- || Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Review, Journal, Metastases: A clinical systematic literature review of treatments among patients with advanced and/or metastatic human epidermal growth factor receptor 2 positive breast cancer. (Pubmed Central) - May 29, 2024
Recruiting --> Active, not recruiting | Trial completion date: Nov 2024 --> Jan 2025 | Trial primary completion date: Sep 2024 --> Jan 2025 Aim: This systematic literature review aims to summarize the efficacy/effectiveness of treatments, including eribulin (ERI)-based and anti-human epidermal growth factor receptor 2 (HER2) treatments in advanced/metastatic HER2+ breast cancer...Longer overall survival (OS) was associated with 1L and 2L treatment, and for 3L+ studies that included ERI, ERI or trastuzumab (Tmab)
- Halaven (eribulin mesylate) / Eisai
Functional paclitaxel and eribulin assay for patient derived xenograft breast cancer tissue ex vivo correlates with in vivo sensitivity in mice (Poster and Exhibition Hall) - May 26, 2024 - Abstract #EACR2024EACR_721;
- | Halaven (eribulin mesylate) / Eisai
Journal, Metastases: Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes. (Pubmed Central) - May 24, 2024
Eribulin demonstrated effective clinical activity and a favorable tolerability profile in Chinese patients with ABC in the real-world. The efficacy and safety profile were consistent with those reported in previous randomized phase 3 trials.
- | Halaven (eribulin mesylate) / Eisai, Aliqopa (copanlisib) / Bayer
Preclinical, Journal, Combination therapy: Evaluation of copanlisib in combination with eribulin in triple negative breast cancer patient-derived xenograft models. (Pubmed Central) - May 8, 2024
These data support further clinical development for the combination of copanlisib and eribulin. These data led to a phase I/II trial of copanlisib and eribulin in patients with metastatic TNBC.
- || Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Clinical data, Journal, Claims database, Metastases: Treatment patterns and clinical outcomes in patients with metastatic triple-negative breast cancer: a large-scale data analysis using the Japanese claims database. (Pubmed Central) - May 5, 2024
This study provides insight into current treatment patterns for mTNBC in Japan. The cost-benefit balance worsens with later-line treatment and a high unmet need for mTNBC drug treatment remains.
- || Halaven (eribulin mesylate) / Eisai
Clinical data, Journal, HEOR, Real-world evidence, Real-world, Metastases: Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior phosphoinositide 3-Kinase inhibitor treatment for metastatic breast cancer. (Pubmed Central) - May 1, 2024
The cost-benefit balance worsens with later-line treatment and a high unmet need for mTNBC drug treatment remains. Our real-world study suggests that eribulin may be a potential treatment option for MBC patients who fail a prior PI3K inhibitor.
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Halaven (eribulin mesylate) / Eisai
New P2 trial, Combination therapy, Metastases: LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer (clinicaltrials.gov) - Apr 29, 2024
P2, N=74, Recruiting, Sponsor: Fudan University
- |||||||||| ESG401 / Escugen Biotechnology, Sorrento
New P3 trial, Metastases: A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer (clinicaltrials.gov) - Apr 25, 2024
P3, N=378, Not yet recruiting, Sponsor: Shanghai Escugen Biotechnology Co., Ltd
- Halaven (eribulin mesylate) / Eisai
Efficacy and safety of eribulin plus gemcitabine in second-line or beyond for patients with HER2-negative metastatic breast cancer (MBC): A multicenter, open-label, single-arm, phase II study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6787;
P2
Clinical trial information: NCT05263882. >TNBC, triple-negative breast cancer.
- Halaven (eribulin mesylate) / Eisai
Eribulin and irinotecan for refractory or recurrent Ewing sarcoma: A retrospective study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6471;
There was no need for further prospective trials on this combination unless mechanisms of synergy and biomarkers are identified. >Data are n (%); % (95% CI) or months (95% CI).
- Halaven (eribulin mesylate) / Eisai
Feasibility and tolerability of eribulin-based chemotherapy versus other chemotherapy regimens for patients with metastatic triple-negative breast cancer: A single-centre retrospective study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6224;
P
Therefore, further investigation of eribulin-based treatment in larger randomized trials for patients with advanced TNBC is warranted. Clinical trial information: NCT05953909.
- Halaven (eribulin mesylate) / Eisai
Clinical outcomes of patients with HR-positive advanced breast cancer treated with eribulin: A retrospective multicenter study from China. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6222;
This retrospective study suggests that eribulin was effective in HR+ Chinese patients with ABC. The front-line and combined therapy of eribulin in HR+ ABC need further exploration.
- Halaven (eribulin mesylate) / Eisai
Treatment (Tx) patterns, efficacy and safety of eribulin for advanced and heavily pretreated breast cancer (ABC): Updated results from a single-center, real-world study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6186;
In this single-center study of pts with heavily pre-treated ABC in China, eribulin Tx resulted in favorable PFS irrespective of molecular subtype, with a manageable safety profile. In pts with a large tumor burden and a good PS, eribulin-based combinations may further improve outcomes.
- Halaven (eribulin mesylate) / Eisai
Efficacy and safety of eribulin-based chemotherapy in patients with advanced breast cancer: A single-centre retrospective study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6168;
Significant PFS benefit was associated with Eribulin treatment in patients with HER2-0 compared with HER2-low. This study still needs longer follow-up to evaluate its efficacy more comprehensively.
- Halaven (eribulin mesylate) / Eisai
Multicentric retrospective study on the treatment characteristics, efficacy and safety of eribulin in Slovenian patients with breast cancer. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6145;
In our population, eribulin was used in the late stages of treatment and in older patients with poorer performance status. The proportion of patients with visceral and CNS tumors was higher.
- Halaven (eribulin mesylate) / Eisai
Survival and safety analysis of eribulin in Indian patients with metastatic breast cancer: A real world clinical experience. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6120;
This study confirms that Eribulin is effective and has manageable toxicity in patients with MBC. It should be considered as the strategy of several chemotherapy lines in MBC.
- sacituzumab tirumotecan (MK-2870) / Merck (MSD)
Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study. (Hall D1) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2909;
P3
trial, SKB264 was compared with physician's choice of chemotherapy (eribulin, vinorelbine, capecitabine, or gemcitabine) in pts with locally recurrent or metastatic TNBC who had received two or more prior therapies including at least one for metastatic setting... Sacituzumab tirumotecan monotherapy demonstrated statistically significant and clinically meaningful PFS and OS benefit over chemotherapy, with a manageable safety profile in pts with heavily pretreated advanced TNBC and limited treatment options.
- Xtandi (enzalutamide capsule) / Pfizer, Astellas, Mifeprex (mifepristone) / Danco Laboratories
TBCRC 058: A randomized phase II study of enzalutamide, enzalutamide with mifepristone, and treatment of physician's choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (NCT06099769). (Hall A; Poster Bd #: 107a) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2567;
P2
Tumors must have AR ?10%, normal organ function, no history of brain mets. As of 1/15/2024, 2 of 201 pts have begun protocol-specified tx.
- BB-1701 / BlissBio, Eisai
An open-label, multicenter, phase 2 study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), in previously treated patients with HER2-positive (HER2+) or HER2-low unresectable or metastatic breast cancer (BC). (Hall A; Poster Bd #: 99a) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2551;
P2
BB-1701 is an ADC consisting of a monoclonal antibody targeting HER2 with eribulin (microtubule inhibitor) as a payload that is capable of exerting a bystander effect...Randomization will be stratified by HER2 status (HER2+ vs. HER2-low) documented prior to T-DXd treatment...In both study parts, exploratory objectives will include evaluation of biomarkers of response to BB-1701 and BB-1701 immunogenicity; other efficacy measures (i.e., PFS on the next line of therapy) and population pharmacokinetics will be analyzed in the dose-expansion part only. Pt enrollment is currently open.
- BB-1701 / BlissBio, Eisai
Updated safety and antitumor activity of BB-1701 from study 101 in the multiple dose level cohort of patients with locally advanced/metastatic HER2-low expressing breast cancer. (Hall A; Poster Bd #: 88) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2540;
P1
Background: BB-1701 is an antibody-drug conjugate (ADC) consisting of a humanized anti-HER2 antibody and eribulin. BB-1701 shows promising antitumor activity and a manageable safety profile in HER2 low-expressing breast cancer, including patients who received prior anti-HER2 ADCs.
- ipatasertib (RG7440) / Roche
Ipatasertib (IPA) combined with non-taxane chemotherapy (CT) for patients (pts) with previously treated advanced triple-negative breast cancer (aTNBC): The PATHFINDER phase IIa trial. (Hall A; Poster Bd #: 76) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2528;
P2
However, adding IPA to CG was not tolerable. E + IPA showed promising efficacy regardless of PI3K/AKT status that merits further evaluation.
- Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trastuzumab and pertuzumab in combination with eribulin mesylate or a taxane as first-line chemotherapeutic treatment for HER2-positive, locally advanced or metastatic breast cancer: Results of a multicenter, randomized, non-inferiority phase 3 trial in Japan (JBCRG-M06/EMERALD). (Hall B1) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2450;
P3
This is the first study to show non-inferiority of eribulin to taxane when used in combination with dual HER2 blockade. As a less toxic but equally effective alternative to the taxane-containing regimen, eribulin combined with HP could be first-line treatment of locally advanced or metastatic HER2+ BC.
- datopotamab deruxtecan (DS-1062a) / Daiichi Sankyo, AstraZeneca
Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2 (Hall B1) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2448;
P3
In TROPION-Breast01, TTD was delayed in the Dato-DXd vs ICC arms for GHS/QoL, physical functioning, pain, and most other symptoms and functioning scales. PRO data complement the improvement in efficacy and manageable safety profile demonstrated with Dato-DXd vs ICC in the primary analysis, supporting Dato-DXd as a potential new, well tolerated therapeutic option in this setting.
- Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors. (Hall A; Poster Bd #: 303) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2129;
P2
Although manageable, neutropenia emerged as a notable adverse effect. These findings underscore the potential of this combination as a therapeutic strategy for advanced solid tumors, warranting further clinical investigation.
- Halaven (eribulin mesylate) / Eisai
A phase III randomized trial of eribulin (E) with gemcitabine (G) vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937 updated design. (Hall A; Poster Bd #: 307a) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1782;
P3
This is an updated phase III, randomized trial comparing GE vs. SOC (SG, docetaxel, paclitaxel, or G monotherapy)...Funding: National Institutes of Health/National Cancer Institute grants U10CA180888, U10CA180819. Eribulin is provided by Eisai.
- Halaven (eribulin mesylate) / Eisai, Focus V (anlotinib) / Advenchen, Sino Biopharm
Safety and efficacy of eribulin plus anlotinib in patients with advanced soft tissue sarcoma (ERAS): A multi-center phase II study. (Hall A; Poster Bd #: 487) - Apr 24, 2024 - Abstract #ASCO2024ASCO_769;
Eribulin is provided by Eisai. The combination of eribulin and anlotinib shows promising efficacy with an acceptable toxicity profile in patients with advanced STS, irrespective of pathological type.
- Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J, Votrient (pazopanib) / Novartis, BeiGene, Halaven (eribulin mesylate) / Eisai
Results of a randomized phase II trial of 2nd-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib: Japan Clinical Oncology Group study JCOG1802 (2ND-STEP). (Hall A; Poster Bd #: 477) - Apr 24, 2024 - Abstract #ASCO2024ASCO_759;
Pazopanib showed the best PFS and OS as the second-line treatment for patients with advanced STS among trabectedin, eribulin, and pazopanib. A phase III trial comparing GD with pazopanib is planned as the next step.
- | Halaven (eribulin mesylate) / Eisai, ML210 / University of Sydney
Journal: Involvement of ferroptosis in eribulin-induced cytotoxicity in ovarian clear cell carcinoma. (Pubmed Central) - Apr 22, 2024
Taken together, our findings show firstly that eribulin triggers ferroptosis in OCCC and this effect occurs via the suppression of the Nrf2-HO-1 signaling pathway, SOD activity and the promotion of lipid peroxidation. These findings suggest that eribulin-induced ferroptosis is associated with its anti-tumor effect and also could be a potential therapeutic target in OCCC.
- | Halaven (eribulin mesylate) / Eisai
Journal: Pharmacological induction of chromatin remodeling drives chemosensitization in triple-negative breast cancer. (Pubmed Central) - Apr 19, 2024
These findings provide an epigenetic mechanism of action of eribulin, supporting its use early in the disease process for MET induction to prevent metastatic progression and chemoresistance. These findings warrant prospective clinical evaluation of the chemosensitizing effects of eribulin in the treatment-naive setting.
- | Ibrance (palbociclib) / Pfizer, Herceptin (trastuzumab) / Roche
Trial completion, Combination therapy, Metastases: PATRICIA: Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer (clinicaltrials.gov) - Apr 17, 2024
P2, N=73, Completed, Sponsor: SOLTI Breast Cancer Research Group
These findings warrant prospective clinical evaluation of the chemosensitizing effects of eribulin in the treatment-naive setting. Active, not recruiting --> Completed
- ||| Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Trial completion date, Metastases: Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] (clinicaltrials.gov) - Apr 11, 2024
P3, N=557, Active, not recruiting, Sponsor: Daiichi Sankyo
Active, not recruiting --> Completed Trial completion date: Mar 2024 --> Oct 2025
- ||||| Piqray (alpelisib) / Novartis, Herceptin (trastuzumab) / Roche
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Metastases: Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) (clinicaltrials.gov) - Apr 9, 2024
P3, N=27, Active, not recruiting, Sponsor: Spanish Breast Cancer Research Group
Trial completion date: Mar 2024 --> Oct 2025 Recruiting --> Active, not recruiting | N=300 --> 27 | Trial completion date: Sep 2026 --> Nov 2024 | Trial primary completion date: Jun 2026 --> Nov 2024
- |||||||||| izalontamab brengitecan (BL-B01D1) / Biokin Pharma, BMS
New P3 trial: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer (clinicaltrials.gov) - Apr 3, 2024
P3, N=382, Not yet recruiting, Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- | Halaven (eribulin mesylate) / Eisai
Journal, Metastases: Effects of Eribulin on the RNA Content of Extracellular Vesicles Released by Metastatic Breast Cancer Cells. (Pubmed Central) - Mar 31, 2024
Then, we performed differential expression analysis, weighted gene co-expression network analysis (WGCNA), functional enrichment analysis, and miRNA-target identification. Our findings demonstrate the possible involvement of EVs from eribulin-treated cells in the spread of chemoresistance, prompting the design of strategies that selectively target tumor EVs.
- || Trodelvy (sacituzumab govitecan-hziy) / Gilead
Review, Journal, Metastases: Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2- Breast Cancer. (Pubmed Central) - Mar 26, 2024
Sacituzumab govitecan demonstrated an overall benefit in terms of health-related quality of life. Current evidence indicates that sacituzumab govitecan is an effective treatment option, with a generally manageable tolerability profile, for patients with pre-treated, unresectable locally advanced or metastatic HR+/HER2- breast cancer.
- ||| ELVN-002 / Enliven Therap
Enrollment open, Metastases: ELVN-002-003: ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer (clinicaltrials.gov) - Mar 26, 2024
P1, N=255, Recruiting, Sponsor: Enliven Therapeutics
Current evidence indicates that sacituzumab govitecan is an effective treatment option, with a generally manageable tolerability profile, for patients with pre-treated, unresectable locally advanced or metastatic HR+/HER2- breast cancer. Not yet recruiting --> Recruiting
- | 5-fluorouracil / Generic mfg.
Journal: Anthracycline-based hepatic arterial infusion chemotherapy achieved 17 (Pubmed Central) - Mar 25, 2024
Not yet recruiting --> Recruiting A 46-year-old woman with estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer who had multiple LMs and bone metastases underwent seven lines of systemic therapy (paclitaxel/bevacizumab for 38
- ||| ELVN-002 / Enliven Therap
New P1 trial, Metastases: ELVN-002-003: ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer (clinicaltrials.gov) - Mar 25, 2024
P1, N=255, Not yet recruiting, Sponsor: Enliven Therapeutics
- Halaven (eribulin mesylate) / Eisai
Real-world (rw) outcomes in patients (pts) with hormone receptor-positive and human epidermal growth factor receptor-2 negative (HR+/HER2-) metastatic breast cancer (mBC) treated with chemotherapy (CT) in France (Exhibition area) - Mar 19, 2024 - Abstract #ESMOBC2024ESMO_BC_507;
HR+/HER2- mBC pts initiating CT in France showed poor survival, decreasing with each subsequent CT line. There is still a high unmet need for improved treatment options in this population.
- || Halaven (eribulin mesylate) / Eisai
Trial completion, Metastases: Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors (clinicaltrials.gov) - Mar 19, 2024
P1, N=8, Completed, Sponsor: City of Hope Medical Center
There is still a high unmet need for improved treatment options in this population. Active, not recruiting --> Completed
- Halaven (eribulin mesylate) / Eisai
Phase classification, Surgery: Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery (clinicaltrials.gov) - Mar 18, 2024
P1, N=15, Active, not recruiting, Sponsor: OHSU Knight Cancer Institute
Active, not recruiting --> Completed Phase classification: P1b --> P1
- | Halaven (eribulin mesylate) / Eisai
Retrospective data, Journal, Metastases: Feasibility and tolerability of eribulin-based chemotherapy versus other chemotherapy regimens for patients with metastatic triple-negative breast cancer: a single-centre retrospective study. (Pubmed Central) - Mar 14, 2024
For the salvage treatment of advanced TNBC, treatment with eribulin produced longer median PFS and OS than other chemotherapy regimens, with a well-tolerated safety profile. Therefore, further investigation of eribulin-based treatment in larger randomized trials for patients with advanced TNBC is warranted.
- | Tyvyt (sintilimab) / Innovent Biologics, Halaven (eribulin mesylate) / Eisai
New P2 trial, Metastases: Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial (clinicaltrials.gov) - Mar 12, 2024
P2, N=81, Not yet recruiting, Sponsor: Zhejiang Cancer Hospital
- ||| TQB2930 / Sino Biopharm
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer (clinicaltrials.gov) - Mar 12, 2024
P1/2, N=154, Recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Therefore, further investigation of eribulin-based treatment in larger randomized trials for patients with advanced TNBC is warranted. N=89 --> 154 | Trial completion date: Oct 2025 --> Oct 2027 | Trial primary completion date: Mar 2025 --> Dec 2026
- | Tukysa (tucatinib) / Pfizer, Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Tucatinib+Trastuzumab+Eribulin in HER2+ MBC (clinicaltrials.gov) - Mar 12, 2024
P2, N=30, Recruiting, Sponsor: Criterium, Inc.
N=89 --> 154 | Trial completion date: Oct 2025 --> Oct 2027 | Trial primary completion date: Mar 2025 --> Dec 2026 Trial completion date: May 2025 --> Aug 2027 | Trial primary completion date: Nov 2023 --> Jun 2027
- | Trodelvy (sacituzumab govitecan-hziy) / Gilead, Halaven (eribulin mesylate) / Eisai
Journal, HEOR, Metastases: Cost-benefit evaluation of advanced therapy lines in metastatic triple-negative breast cancer in Germany. (Pubmed Central) - Mar 9, 2024
In Germany, the efficiency frontier can provide decision support for the pricing of innovative interventions. Results of our analysis may thus guide reimbursement determination.